Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Author(s): Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, et al.

Abstract

Objective: To determine the relation between exposure to glycaemia over time and the risk of macrovascular or microvascular complications in patients with type 2 diabetes.

Design: Prospective observational study.

Setting: 23 hospital based clinics in England, Scotland, and Northern Ireland.

Participants: 4585 white, Asian Indian, and Afro-Caribbean UKPDS patients, whether randomised or not to treatment, were included in analyses of incidence; of these, 3642 were included in analyses of relative risk.

Outcome measures: Primary predefined aggregate clinical outcomes: any end point or deaths related to diabetes and all cause mortality. Secondary aggregate outcomes: myocardial infarction, stroke, amputation (including death from peripheral vascular disease), and microvascular disease (predominantly retinal photo-coagulation). Single end points: non-fatal heart failure and cataract extraction. Risk reduction associated with a 1% reduction in updated mean HbA(1c) adjusted for possible confounders at diagnosis of diabetes.

Results: The incidence of clinical complications was significantly associated with glycaemia. Each 1% reduction in updated mean HbA(1c) was associated with reductions in risk of 21% for any end point related to diabetes (95% confidence interval 17% to 24%, P<0.0001), 21% for deaths related to diabetes (15% to 27%, P<0.0001), 14% for myocardial infarction (8% to 21%, P<0.0001), and 37% for microvascular complications (33% to 41%, P<0.0001). No threshold of risk was observed for any end point.

Conclusions: In patients with type 2 diabetes the risk of diabetic complications was strongly associated with previous hyperglycaemia. Any reduction in HbA(1c) is likely to reduce the risk of complications, with the lowest risk being in those with HbA(1c) values in the normal range (<6.0%).

Similar Articles

Global guidelines for type 2 diabetes

Author(s): IDF Clinical Guidelines Task Force

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

Author(s): Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, et al.

Computer modeling of diabetes and its complications

Author(s): The Mount Hood 4 Modeling Group

A clinical prediction rule for delirium after elective noncardiac surgery

Author(s): Marcantonio ER, Goldman L, Mangione CM, Ludwig LE, Muraca B, et al.

Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study

Author(s): van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, et al.

The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)

Author(s): Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group

Risk factors for diabetic peripheral sensory neuropathy

Author(s): Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, et al.

Risk factors for renal dysfunction in type 2 diabetes: U

Author(s): Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR

Preserving renal function in adults with hypertension and diabetes: a consensus approach

Author(s): Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, et al.

Incidence and determinants of microalbuminuria in Koreans with type 2 diabetes

Author(s): Park JY, Kim HK, Chung YE, Kim SW, Hong SK, et al.

Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension

Author(s): Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, et al.

The Metabolic Syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects

Author(s): Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, et al.